golimumab · Simponi

Monoclonal antibody

Also known as CNTO 148

Approvedregulatory verdict

Evidence outlook

Approved: Psoriatic Arthritis, Ulcerative Colitis (label: Adults with moderately to severely active UC who have had an inadequate response to conventional...), Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Crohn's Disease · Phase 2

Also approved (5)
US
  • Adult patients with active ankylosing spondylitis (AS)
Product first approved 2009Outside this platform's coverageFDA label
UK
  • Moderately to severely active ulcerative colitis in adult patients
Product first approved 2013medicines.org.uk
JP
  • Treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not sufficiently responded to conventional treatments
Product first approved 2011PMDA
EU
  • Rheumatoid arthritis (RA) Simponi, in combination with methotrexate (MTX), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX. Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function. For information regarding the polyarticular juvenile...
Product first approved 2009EMA
CA
  • SIMPONI® (golimumab injection) Rheumatoid Arthritis (RA) Simponi, in combination with methotrexate (MTX), is indicated for: • Reducing signs and symptoms and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. • Inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who had not previously been treated with MTX. Psoriatic Arthritis (PsA) Simponi is indicated for: • Reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in...
Product first approved 2009Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (28)
Psoriatic Arthritis
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT04108468 · The Leeds Teaching Hospitals NHS Trust
2015-10-27 – 2023-07 · Psoriatic Arthritis
What this study did
NCT01871649 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2013-08 – 2018-11 · Psoriatic Arthritis
What this study did
NCT02065713 · Instituto de Medicina Molecular João Lobo Antunes
2014-08 – 2017-06 · Psoriatic Arthritis
What this study did
NCT02181673 · Janssen Research & Development, LLC
2014-09-08 – 2017-03-22 · Arthritis, Psoriatic
What this study did
NCT00265096 · Centocor, Inc.
2005-12 – 2012-01 · Arthritis, Psoriatic
What this study did
Rheumatoid Arthritis
NCT00973479 · Centocor, Inc.
2009-09 – 2013-02 · Arthritis, Rheumatoid
What this study did
NCT01248780 · Centocor, Inc.
2010-09 – 2012-07 · Rheumatoid Arthritis
What this study did
NCT00975130 · Merck Sharp & Dohme LLC
2009-09 – 2012-02 · Arthritis, Rheumatoid
What this study did
NCT00727987 · Janssen Pharmaceutical K.K.
2008-05 – 2011-12 · Rheumatoid Arthritis
What this study did
NCT00771251 · Janssen Pharmaceutical K.K.
2008-05 – 2011-10 · Rheumatoid Arthritis
What this study did
NCT00361335 · Centocor, Inc.
2006-09 – 2009-09 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
Other / comorbidity
NCT03270501 · University Ghent
2017-11-08 – 2023-12-14 · Axial Spondyloarthritis
What this study did
NCT01426815 · University Hospital, Ghent
2012-03-13 – 2019-03-18 · Peripheral Spondylarthritis
What this study did
NCT02186873 · Janssen Research & Development, LLC
2014-09-03 – 2016-10-11 · Ankylosing Spondylitis
What this study did
NCT01453725 · Merck Sharp & Dohme LLC
2012-02-13 – 2015-01-15 · Spondylitis, Ankylosing
What this study did
NCT01230827 · Janssen Research & Development, LLC
2010-12 – 2014-05 · Juvenile Idiopathic Arthritis
What this study did
NCT01248793 · Centocor, Inc.
2010-10 – 2012-03 · Ankylosing Spondylitis
What this study did
NCT00265083 · Centocor, Inc.
2005-12 – 2012-01 · Spondylitis, Ankylosing
What this study did
Phase 2/3 (2)
Ulcerative Colitis
NCT00488774 · Janssen Research & Development, LLC
2007-08 – 2009-05 · Colitis, Ulcerative
What this study did
Phase 2 (16)
Crohn's Disease
NCT05242471 · Janssen Research & Development, LLC
2022-07-22 – 2029-11-05 · Crohn's Disease
What this study did
Psoriatic Arthritis
NCT05071664 · Janssen Research & Development, LLC
2021-10-25 – 2024-08-06 · Arthritis, Psoriatic
What this study did
Rheumatoid Arthritis
NCT01715896 · MedImmune LLC
2013-03 – 2015-02 · Rheumatoid Arthritis
What this study did
NCT00207714 · Centocor, Inc.
2003-11 – 2006-02 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05242484 · Janssen Research & Development, LLC
2022-09-19 – 2029-03-27 · Colitis, Ulcerative
What this study did
NCT03182166 · Centre Hospitalier Universitaire de Saint Etienne
2017-11-21 – 2021-12-15 · Ulcerative Colitis
What this study did
NCT03662542 · Janssen Research & Development, LLC
2018-11-20 – 2021-11-15 · Colitis, Ulcerative
What this study did
Other / comorbidity
NCT07683026 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2026-08-08 – 2032-09-01 · Type 1 Diabetes (T1D)
What this study did
NCT04729296 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2021-07-01 – 2027-07-01 · Diabetes Mellitus, Type 1
What this study did
NCT05960578 · University of Washington
2024-05-23 – 2026-04-14 · Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
What this study did
NCT04218565 · Wenjie Zheng
2020-02-15 – 2022-12-15 · Behcet Syndrome, Uveitis
What this study did
NCT02846545 · Janssen Research & Development, LLC
2016-08-26 – 2021-01-05 · Diabetes Mellitus, Type 1
What this study did
NCT00675649 · Centocor, Inc.
started 2008-05 · Asthma
What this study did
NCT00207740 · Centocor, Inc.
2004-08 – 2007-07 · Asthma
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01526174 · House Research Institute
2012-03 – 2014-04 · Autoimmune Inner Ear Disease
What this study did
Phase 1 (7)
Psoriatic Arthritis
NCT04152759 · Bio-Thera Solutions
2019-09-09 – 2020-12-31 · Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT01362153 · Centocor, Inc.
2007-12-26 – 2009-02-27 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
Other / comorbidity
NCT03632759 · Carla Greenbaum, MD
2018-08-15 – 2021-11-09 · Type 1 Diabetes Mellitus
What this study did
NCT03298542 · Janssen Research & Development, LLC
2017-10-16 – 2021-06-01 · Pre-Symptomatic Type 1 Diabetes
What this study did
NCT01258777 · Centocor, Inc.
2010-10 – 2011-04 · Healthy Volunteers
What this study did
NCT01288157 · Centocor, Inc.
2010-09 – 2011-01 · Healthy Adult Chinese Males
What this study did
Phase 4 (22)
Psoriatic Arthritis
NCT03733925 · Johnson & Johnson Private Limited
2019-01-07 – 2021-11-15 · Spondylitis, Ankylosing, Arthritis, Psoriatic
What this study did
Rheumatoid Arthritis
NCT01602302 · Medical University of Graz
2012-06 – 2020-11-19 · Rheumatoid Arthritis
What this study did
NCT01295151 · Julia Brown
2011-08 – 2015-11 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT04156984 · David Drobne
2021-04-07 – 2024-06-18 · Ulcerative Colitis
What this study did
NCT02425865 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2016-12 – 2023-01 · ULCERATIVE COLITIS
What this study did
NCT01804166 · Janssen Scientific Affairs, LLC
2013-03-21 – 2020-02-28 · Hepatosplenic T-Cell Lymphoma
What this study did
NCT03669029 · Hospital de Manises
2018-10-01 – 2019-12-31 · Colitis, Ulcerative
What this study did
NCT03124121 · Guy's and St Thomas' NHS Foundation Trust
2017-09-05 – 2019-09-30 · Ulcerative Colitis
What this study did
NCT02910375 · Universitaire Ziekenhuizen KU Leuven
2016-12 – 2018-05 · Ulcerative Colitis
What this study did
NCT02318667 · Merck Sharp & Dohme LLC
2015-02-27 – 2017-09-05 · Colitis, Ulcerative
What this study did
NCT02412085 · Istituto Clinico Humanitas
2015-03 – 2017-01 · Colitis, Ulcerative
What this study did
NCT02092285 · Merck Sharp & Dohme LLC
2014-05-09 – 2016-05-25 · Ulcerative Colitis
What this study did
NCT02186886 · Kliniken im Naturpark Altmuehltal
2014-06 – 2015-12 · Ulcerative Colitis
What this study did
NCT02155335 · Merck Sharp & Dohme LLC
2014-07-01 – 2015-10-05 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT07904780 · Oslo University Hospital
2026-11-11 – 2030-11-11 · Juvenile Idiopathic Arthritis (JIA)
What this study did
NCT05164198 · Hanyang University Seoul Hospital
2022-01-15 – 2024-10-31 · Ankylosing Spondylitis, Axial Spondyloarthritis
What this study did
NCT03253796 · Merck Sharp & Dohme LLC
2017-11-07 – 2021-03-17 · Spondyloarthritis
What this study did
NCT02758782 · Charite University, Berlin, Germany
2016-09 – 2021-01 · Ankylosing Spondylitis
What this study did
NCT02687724 · University College Dublin
2016-06 – 2020-02 · Colitis
What this study did
NCT01668004 · Merck Sharp & Dohme LLC
2012-09-03 – 2015-04-30 · Ankylosing Spondylitis
What this study did
NCT01718951 · Tuen Mun Hospital
2012-08 – 2014-10 · Spondyloarthropathy
What this study did
NCT01212653 · Chinese University of Hong Kong
2010-10 – 2013-05 · Ankylosing Spondylitis(AS)
What this study did
Early phase / not applicable (6)
Psoriatic Arthritis
NCT02841176 · Imperial College Healthcare NHS Trust
2016-07 – 2017-09-19 · Psoriatic Arthritis
What this study did
Ulcerative Colitis
NCT02729233 · University of Arkansas
2017-01 – 2017-01-27 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT04156425 · Shanghai Mental Health Center
2020-07-01 – 2024-12-31 · Major Depressive Disorder
What this study did
NCT04531423 · Shanghai Mental Health Center
2020-10-01 – 2022-09-30 · Major Depressive Disorder
What this study did
NCT01610947 · University Hospital, Montpellier
2012-05-14 – 2018-10-18 · Spondyloarthritis
What this study did
NCT01088698 · Medical University of Graz
2010-03 – 2010-10 · Psoriasis
What this study did
Used as active comparator (9)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Psoriatic Arthritis
NCT05669833 · University of Pennsylvania
2023-07-14 – 2027-01 · Psoriatic Arthritis
What this study did
NCT05046431 · Bio-Thera Solutions
2021-05-06 – 2023-10-06 · Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT03414502 · University of Nebraska
2007-12-10 – 2029-03 · Rheumatoid Arthritis
What this study did
NCT05842213 · Alvotech Swiss AG
2023-03-30 – 2024-09-24 · Rheumatoid Arthritis
What this study did
Phase 2 (1)
Rheumatoid Arthritis
NCT01217814 · Sanofi
2010-11 – 2011-09 · Rheumatoid Arthritis
What this study did
Phase 1 (2)
Psoriatic Arthritis
NCT05332730 · Bio-Thera Solutions
2022-08-01 – 2023-07-10 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT05632211 · Alvotech Swiss AG
2022-12-16 – 2023-10-03 · Healthy Adult Subjects
What this study did
Phase 4 (2)
Rheumatoid Arthritis
NCT03100253 · Mario Negri Institute for Pharmacological Research
2018-03-01 – 2021-12-31 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05313620 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2022-04-01 – 2026-06-11 · Ulcerative Colitis, Thromboembolism
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Other / comorbidity
NCT02437162 · Janssen Research & Development, LLC
2015-09-03 – 2017-09-06 · Axial Spondyloarthritis
What this study did
NCT02438787 · Janssen Research & Development, LLC
2015-07-31 – 2017-08-31 · Axial Spondyloarthritis
What this study did
Phase 4 (1)
Ulcerative Colitis
NCT03885713 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2019-09-10 – 2024-12-31 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Ulcerative Colitis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Golimumab (Simponi): this drugApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT01863771: Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4)
NCT00488631: Number of Participants in Clinical Response Through Week 54 (Induction Baseline, Week 0 through Week 54): Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance 48/154 (31.2%) vs GLM-I-Rsp-Golimumab 50 mg Maintenance 71/151 (47.0%) vs GLM-I-Rsp-Golimumab 100 mg Maintenance 75/151 (49.7%); p=0.010 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 50 mg Maintenance), p=<0.001 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 100 mg Maintenance)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00408629: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo)
NCT02065557: Induction (Week 8, ITT-E, Main Study): I-SD 43.3% vs external placebo 19.83% (p=0.382, NS); I-HD 59.6% vs external placebo (p<0.001); combined I-SD+I-HD 53.2% (p<0.001). Maintenance (Week 52, mITT-E): M-PL 33.3% (n=12, descriptive only); M-SD 29.0% vs external placebo 18.37% (p=0.382, NS); M-HD 45.2% (p<0.001); combined M-SD+M-HD 37.1% (p<0.001).
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Balsalazide Disodium (Colazal)
ApprovedUS marketing discontinued
Small moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Uceris Rectal Foam)ApprovedSmall moleculeGlucocorticoid receptorReliable signalNo reviewed efficacy summary in this indication
Budesonide MMX (Uceris)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT01532648: Registered primary, clinical remission at day 56 (UCDAI rectal bleeding and stool frequency subscores of 0), budesonide MMX 9 mg vs placebo added to oral mesalamine: 56/230 vs 52/228 (CT.gov); similar in both groups, p=0.70 (Rubin 2017). Combined clinical and endoscopic remission at week 8: 13.0% vs 7.5%, p=0.049. missed
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Etrasimod (Velsipity)ApprovedSmall moleculeS1P receptorReliable signal
NCT03945188: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo)
NCT03996369: Percentage of Participants Achieving Clinical Remission (Week 12): Etrasimod 2 mg 24.8% vs Placebo 15.2%; p==0.026 (Etrasimod 2 mg vs Placebo)
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT05528510: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8)
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Hydrocortisone (Cortenema)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Hydrocortisone Acetate (Cortifoam)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaWeak signal
NCT01585155: Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%
NCT00336492: The Number of Participants With Clinical Response at Week 8 (Week 8): Infliximab 5 mg/kg 44/60 (73.3%)
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Apriso)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Canasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Lialda)ApprovedSmall moleculeAminosalicylateReliable signal
NCT00151892: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months (6 Months): SPD476 83.7 percent of participants | Asacol 81.5 percent of participants
Mesalamine (Pentasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Rowasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03524092: Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) (Week 40): Maintenance Period: Miri IR - 200 mg Miri SC 49.9% (95% CI 44.7 to 55) vs Maintenance Period: Miri IR - PBO SC 25.1% (95% CI 18.8 to 31.5)
NCT03518086: Percentage of Participants With Clinical Remission at Week 12 (Week 12): Placebo IV Q4W 13.3% (95% CI 6.9-19.6) vs 300 mg Mirikizumab IV Q4W 24.2% (95% CI 19.5-28.9); p=0.00006 (Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W)
Olsalazine (Dipentum)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Ozanimod (Zeposia)ApprovedSmall moleculeS1P receptorReliable signal
NCT02435992: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period))
NCT03915769: Clinical response at week 12: 52.9% (0.46 mg) and 61.5% (0.92 mg) vs 32.3% placebo.
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
INSPIRE/COMMAND: clinical remission + endoscopic improvement met
NCT03398148: Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score (Week 12): Substudy 1, Induction Period 1: Double-blind Placebo IV 1/60 (1.7%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV 7/61 (11.5%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV 6/61 (9.8%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV 6/58 (10.3%) vs Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV 42/340 (12.4%); p=0.0324 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV), p=0.0460 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV), p=0.0397 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV)
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3Reliable signal
NCT01458574: Percentage of Participants In Remission at Week 52 (Week 52): Tofacitinib 5 mg BID 34.3% vs Tofacitinib 10 mg BID 40.6% vs Placebo 11.1%; p=<0.0001 (Tofacitinib 5 mg BID vs Placebo), p=<0.0001 (Tofacitinib 10 mg BID vs Placebo)
NCT01458951: Percentage of Participants With Remission at Week 8 (Week 8): Tofacitinib 10 mg BID 16.6% vs Placebo BID 3.6%; p=0.0005 (Tofacitinib 10 mg BID vs Placebo BID)
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03653026: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (Week 8): Upadacitinib 45 mg 33.5% (95% CI 28.5-38.5) vs Placebo 4.1% (95% CI 1.1-7.1); p=<0.001 (Upadacitinib 45 mg vs Placebo)
NCT02819635: Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (At Week 8): SS1: Placebo 0% vs SS1: Upadacitinib 7.5 mg 8.5% vs SS1: Upadacitinib 15 mg 14.3% vs SS1: Upadacitinib 30 mg 13.5% vs SS1: Upadacitinib 45 mg 21.4%; p=0.049 (SS1: Placebo vs SS1: Upadacitinib 7.5 mg), p=0.010 (SS1: Placebo vs SS1: Upadacitinib 15 mg), p=0.007 (SS1: Placebo vs SS1: Upadacitinib 30 mg), p=<0.001 (SS1: Placebo vs SS1: Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT02407236: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Week 8): Induction Study (IS): Placebo Intravenous (IV) 17/319 (5.3%) vs IS: Ustekinumab 130 Milligram (mg) IV 50/320 (15.6%) vs IS: Ustekinumab Approximately 6 mg/kg IV 50/322 (15.5%); p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab 130 Milligram (mg) IV), p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab Approximately 6 mg/kg IV)
NCT04630028: Week 8 clinical remission 25% (27/107) after IV induction; the study's primary endpoint is week 52 remission in week 8 responders.
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinReliable signal
NCT02497469: Percentage of Participants Who Achieved Clinical Remission (Week 52): Adalimumab SC, 160/80/40 mg 22.5% (95% CI 18.5-27.0) vs Vedolizumab IV 300 mg 31.3% (95% CI 26.7-36.2); p=0.0061 (Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg)
NCT02611830: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 14.3% (95% CI 6.4-26.2) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 46.2% (95% CI 36.5-56.2) vs Maintenance Phase: Induction IV + Vedolizumab 300 mg IV 42.6% (95% CI 29.2-56.8); p=<0.001 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
Mesalamine (Asacol HD)US approval withdrawnSmall moleculeAminosalicylatePartial signalNo reviewed efficacy summary in this indication
AfimkibartPhase 3Monoclonal antibodyTL1APartial signal
NCT04090411: Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 (At Week 14): Induction Period: Placebo 11.6% (95% CI 5.77-22.88) vs Induction Period: PF-06480605 50 mg 25.5% (95% CI 15.44-37.19) vs Induction Period: PF-06480605 150 mg 23.3% (95% CI 14.98-33.98) vs Induction Period: PF-06480605 450 mg 23.9% (95% CI 16.58-32.06); p=0.0545 (Induction Period: Placebo vs Induction Period: PF-06480605 50 mg), p=0.0823 (Induction Period: Placebo vs Induction Period: PF-06480605 150 mg), p=0.0642 (Induction Period: Placebo vs Induction Period: PF-06480605 450 mg) missed
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
Icotrokinra (Icotyde)Phase 3PeptideIL-23 receptorReliable signal
NCT06049017: Primary endpoint clinical response at Week 12: 63.5% with the highest icotrokinra dose vs 27% with placebo (p<0.001)
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MufemilastPhase 3Small moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 3Small moleculemiR-124Reliable signal
NCT05535946: ABTECT maintenance, clinical remission at Week 44: placebo 10.4% (20), 25 mg 50.8% (98; placebo-adjusted +39.3%), 50 mg 51.3% (100; placebo-adjusted +40.3%), p<0.0001
NCT05507203: ABTECT-1 (NCT05507203), clinical remission at Week 8: placebo 2.5% (4/158), 25 mg 23.8% (38/160, p<0.0001), 50 mg 21.7% (69/318, p<0.0001; placebo-adjusted +19.3%)
PonesimodPhase 3Small moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1AReliable signal
NCT06052059: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints.
NCT04996797: Remission 26% vs 1% placebo; +25pp (95% CI 14–37)
AC-101Phase 2Small moleculeRIPK2not yet gradedNo reviewed efficacy summary in this indication
ALTB-268Phase 2Monoclonal antibodyPSGL-1Weak signalNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorReliable signal
NCT04857112: Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002)
ATH-063Phase 2Small moleculeG9A (EHMT2)Weak signalFeatured results are safety only in this race
BI 3032950Phase 2Monoclonal antibodyTREM-1not yet gradedNo reviewed efficacy summary in this indication
CU104Phase 2Small moleculeEndothelial barrier functionPartial signalNo reviewed efficacy summary in this indication
GarutadustatPhase 2Small moleculePHD1/2not yet gradedNo reviewed efficacy summary in this indication
HRS-7085Phase 2Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
HSK47388Phase 2PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
IPG11406Phase 2Small moleculeEBI2Weak signalFeatured results are safety only in this race
Live SK08Phase 2Microbiome therapeuticLive biotherapeutic productnot yet gradedNo reviewed efficacy summary in this indication
MK-8690Phase 2Monoclonal antibodyCD30 ligand (CD30L / CD153)not yet gradedNo reviewed efficacy summary in this indication
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Nanosomal TacrolimusPhase 2Small moleculeCalcineurinnot yet gradedNo reviewed efficacy summary in this indication
Nomelcitinib (D-2570)Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
OD-07656Phase 2Small moleculeRIPK2Weak signalNo reviewed efficacy summary in this indication
OlamkiceptPhase 2Protein / enzyme therapeuticIL-6 transPartial signal
NCT03235752: Clinical response at Week 12: 58.6% olamkicept 600mg vs 34.5% placebo, P=0.032.
OmilancorPhase 2Small moleculeLANCL2Partial signal
NCT03861143: Clinical Remission (Week 12): BT-11 Low-dose (440 mg) 30.3% | BT-11 High-dose (880 mg) 31.8% vs Placebo 22.7%
PALI-2108Phase 2Small moleculePDE4Weak signalFeatured results are safety only in this race
PicankibartPhase 2Monoclonal antibodyIL-23 p19Partial signal
NCT05377580: Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05).
PL8177Phase 2PeptideMC1Rnot yet gradedNo reviewed efficacy summary in this indication
ZotemtegrastPhase 2Small moleculeα4β7 integrinWeak signal
NCT05611671: Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): MORF-057 200 mg BID 31.9% | MORF-057 100 mg BID 23.9% | MORF-057 100 mg QD-M 17.1% vs Placebo 24.3% missed
NCT05291689: Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score (From baseline to 12 weeks): MORF-057 (Main Cohort) -6.4 score on a scale (Standard Deviation 11.18)
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 1/2Cell therapyAllogeneic MSC therapynot yet gradedNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ExoFloPhase 1Cell therapyMSC-derived exosomesWeak signalNo reviewed efficacy summary in this indication
LMT503Phase 1Small moleculeMacrophage polarization / Cellular metabolismnot yet gradedNo reviewed efficacy summary in this indication
R-3750Phase 1Biologic (subtype unspecified)Dendritic cell targetingnot yet gradedNo reviewed efficacy summary in this indication
SOR102Phase 1Biologic (subtype unspecified)TNF-alpha, IL-23 p19Weak signalFeatured results are safety only in this race
TQH3906Phase 1Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
BalinatunfibDiscontinuedSmall moleculeTNF-alphanot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 88 furthest-along competitors are listed; 26 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Simponi (golimumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
November 2029 (1)
Phase 4Juvenile Idiopathic Arthritis (JIA)Not yet recruiting
Est. primary completion 2029-11-11 · NCT07904780 · CT.gov ↗
What to watch
2032 (1)
September 2032 (1)
Phase 2Type 1 Diabetes (T1D)Not yet recruiting
Est. primary completion 2032-09-01 · NCT07683026 · CT.gov ↗
What to watch

See the full readout calendar ↗